Physician profile
Robert Scheinberg
NPI 1053320010
$2,194,288.94
in general payments reported to CMS, 2019-2025
17 companies · $891 in 2025
The $891 reported for 2025 was more than what a typical Sports Medicine (Orthopaedic Surgery) provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282K · 2020: $598 · 2021: $2,617 · 2022: $1,994 · 2023: $1.9M · 2024: $879 · 2025: $891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $1.9M · Food and Beverage: $2,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $1,905,000.00 |
| Food and Beverage | $2,119.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $2,185,107.60 | 2019-2023 | |
| Pylant Medical | $4,775.11 | 2019-2024 | |
| Stryker Corporation | $3,007.49 | 2019-2025 | Iconix, Alphavent, Salvation |
| Ferring Pharmaceuticals INC. | $386.05 | 2021-2025 | Euflexxa |
| Sanofi-Aventis U.S. LLC | $211.32 | 2020-2023 | |
| Vericel Corporation | $155.23 | 2023 | Maci |
| Vertex Pharmaceuticals Incorporated | $125.78 | 2025 | |
| Smith+Nephew, INC. | $119.25 | 2019-2024 | N/A, Renasys Touch |
| Merck Sharp & Dohme LLC | $80.60 | 2022-2024 | Bridion |
| Cumberland Pharmaceuticals, INC. | $75.46 | 2019-2023 | Caldolor |
| Depuy Synthes Sales INC. | $73.46 | 2020-2025 | Orthovisc, Monovisc |
| Pacira Therapeutics, INC. | $51.15 | 2019-2020 | |
| Bioventus LLC | $46.61 | 2025 | Exogen Ultrasound Bone Healing System |
| Axogen | $25.28 | 2023 | Avance Nerve Graft |
| Pacira Pharmaceuticals Incorporated | $18.63 | 2025 | Exparel |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $18.10 | 2025 | Tremfya |
| Zimmer Biomet Holdings, INC. | $11.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Scheinberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.